MOTS-c for weight loss is an early research idea, not an established treatment. In mice fed a high-fat diet, the mitochondrial peptide MOTS-c limited weight gain and insulin resistance, largely through a cellular energy sensor called AMPK. No controlled human trial has shown that injected MOTS-c causes weight loss, and MOTS-c is not FDA-approved for any use.
MOTS-c for weight loss is one of the fastest-rising peptide searches of the year. The mouse data are striking, but a striking mouse study and a weight-loss treatment are two very different things.
This guide is about that gap. It covers what the diet-induced obesity studies found, how AMPK fits in, what has not been shown in humans, how the evidence compares with approved GLP-1 medicines, and who might reasonably raise MOTS-c with a provider. Also searched as: mots c, motsc, mots-c peptide, peptide mots-c, mots-c weight loss and mots-c fat loss.
What is MOTS-c, and why is it linked to weight loss?
MOTS-c is a 16-amino-acid peptide. Its name stands for mitochondrial open reading frame of the 12S rRNA type-c, which tells you where it comes from: a short stretch of the mitochondrial genome. It was first described by a University of Southern California team in 2015 (Lee et al., 2015).
Researchers think it acts as a signal that helps cells respond to metabolic stress. Its main target in that first paper appeared to be skeletal muscle, a major site of glucose uptake after a meal. That muscle focus is a big part of why MOTS-c for weight loss became a talking point.
For the full background on the molecule, see our MOTS-c metabolic research overview and the plain-English explainer on what the MOTS-c peptide is.
Curious whether MOTS-c fits your health history? Complete a short online intake. A US-licensed provider reviews it asynchronously, with no scheduled appointment, and decides whether a prescription is appropriate.
See if MOTS-c is right for youMOTS-c for weight loss: what the mouse studies found
The story starts with diet-induced obesity (DIO) mouse models: mice fed a high-fat diet until they gain weight and become insulin resistant.
Key studies reported:
| Study | Model | What was reported |
|---|---|---|
| Lee et al., 2015 | Mice on a high-fat diet, and aging mice | MOTS-c treatment prevented diet-induced obesity and high-fat-diet insulin resistance, and acted through the folate cycle and AMPK |
| Kim et al., 2019 | Diet-induced obese mice | MOTS-c injection was linked to more fat burning (beta-oxidation), less fat accumulation and lower fatty liver, with shifts in plasma metabolites |
| Kim et al., 2018 | Cells under metabolic stress | MOTS-c moved into the nucleus and changed gene expression in an AMPK-dependent way |
| Reynolds et al., 2021 | Young, middle-aged and old mice, plus human exercise samples | MOTS-c improved physical capacity in mice, and exercise raised natural MOTS-c in human muscle and blood |
Every weight and fat finding is in mice. The human data concern exercise raising your own MOTS-c, not injecting it.
Why DIO mouse results do not translate neatly
Mice burn energy much faster than people relative to their size, and they live on fixed diets in controlled cages. Plenty of compounds that slim down DIO mice never show a meaningful effect in human trials. That is why MOTS-c weight loss claims online, which jump straight from mouse to human, deserve caution.
How MOTS-c and AMPK connect to metabolism
AMPK is often called the cell's fuel gauge. When energy runs low, as it does during exercise or fasting, AMPK switches on. It nudges cells to take up more glucose and burn more fat.
In the 2015 paper, MOTS-c inhibited the folate cycle and the purine production tied to it. That led to a build-up of a molecule called AICAR, a known AMPK activator. That is why it gets labelled an exercise mimetic, a theme covered in depth in our MOTS-c exercise mimetic explainer.
The AMPK link is also why MOTS-c is compared with metformin. Our MOTS-c vs metformin comparison walks through how the two differ, and the MOTS-c insulin resistance guide covers the glucose side of the research.
A note for athletes: because of this AMPK action, MOTS-c is listed on the World Anti-Doping Agency (WADA) Prohibited List at all times under S4.4.1, activators of AMPK, as USADA explains in its MOTS-c athlete guide. Tested athletes should check the current list and their federation's rules.
What MOTS-c for weight loss has not shown in humans
Here is what is missing from the evidence on MOTS-c for weight loss:
- No controlled weight-loss trial. There is no published randomized, placebo-controlled trial of injected MOTS-c for body weight in people.
- No established human dose. Online dosage charts are not based on human trials. Our guide to how providers approach MOTS-c dosing explains why the dose is set individually.
- Limited human safety data. Reported or theorised effects include injection-site reactions, fatigue, headache, nausea and changes in blood sugar. See the MOTS-c side effects overview.
- Unclear role of natural levels. Blood levels in obesity are inconsistent across studies, as the next section shows.
What MOTS-c obesity research says about natural levels
MOTS-c obesity research in humans has mostly measured how much of the peptide people already have. A small Chilean study of 20 adults found plasma MOTS-c was similar in lean and obese participants, and linked to insulin sensitivity only in the lean group (Cataldo et al., 2018). A 2024 meta-analysis of seven studies and 602 participants found lower levels in people with diabetes but higher levels in people with obesity (Zhou et al., 2024).
Those are observations, not treatment results. They do not show that adding more MOTS-c leads to fat loss.
Want a licensed provider to weigh the early MOTS-c research against your own goals and medications? Start a short online intake. Every prescription is subject to medical approval by a licensed provider.
Learn about the MOTS-c protocolMOTS-c vs GLP-1 medicines: comparing the evidence
Many people searching for peptides for weight loss are also weighing GLP-1 medicines. The fair comparison is how much human testing each has had.
| Question | MOTS-c | Approved GLP-1 medicines |
|---|---|---|
| Main research setting | Mice and cells | Large randomized human trials |
| Example trials | None published for weight in humans | STEP 1 was a 68-week trial in 1,961 adults (Wilding et al., 2021); SURMOUNT-1 was a 72-week trial in 2,539 adults (Jastreboff et al., 2022) |
| How it is studied to work | AMPK and muscle energy use | Appetite, fullness and blood sugar hormones |
| FDA status | Not FDA-approved for any use | Brand-name semaglutide and tirzepatide products are FDA-approved for chronic weight management |
If weight management is your main goal, a GLP-1 conversation may be the better starting point simply because the human evidence base is so much larger. Our GLP-1 blog explains how GLP-1 medicines work. For a side-by-side look at other peptides in this space, see our peptides for weight loss guide covering AOD-9604 and MOTS-c.
Who might discuss MOTS-c for weight loss with a provider
MOTS-c for weight loss is best thought of as a metabolic-health conversation, not a diet product. People who tend to raise it include:
- Adults interested in metabolic health who understand the evidence is early and already focus on exercise, nutrition and sleep.
- Those who want a supervised prescription route instead of grey-market vials sold as "research use only," which have unverified identity, strength and sterility.
Some people need extra caution or should avoid it. Anyone pregnant or breastfeeding should not use MOTS-c. Because it is studied for effects on glucose, people taking insulin or other diabetes medication need a provider to consider blood sugar changes. A provider decides whether it is appropriate at all.
How the telos rx process works
- Online intake. You answer questions about your health, medications and goals.
- Asynchronous provider review. A US-licensed provider reviews your answers, with no scheduled call. A prescription is required, and approval is not guaranteed.
- Licensed pharmacy. If approved, a licensed US pharmacy compounds MOTS-c as a subcutaneous injection. Your provider sets the dose and schedule. If you are new to injections, our how to inject MOTS-c guide covers the basics your care team walks you through.
- Ongoing support. You can message the care team, and plans can be cancelled from your portal.
telos rx does not offer oral or tablet MOTS-c. Full details are on the MOTS-c page.
Regulatory status of the MOTS-c peptide
MOTS-c is not FDA-approved, and compounded MOTS-c has not been evaluated by the FDA for safety or effectiveness. In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding MOTS-c to the list of bulk substances for compounding. FDA's briefing documents had recommended against. The vote is advisory and non-binding, pending FDA rulemaking. On October 28, 2026, HHS announced an interim enforcement discretion policy that includes MOTS-c: HHS does not intend to take enforcement action against state-licensed pharmacies that compound single-ingredient MOTS-c for subcutaneous or intramuscular injection with a valid prescription, if strict sourcing, testing and reporting conditions are met. It is temporary while FDA decides through rulemaking, it is not FDA approval, and HHS can revisit it. Our PCAC vote explainer and the MOTS-c legal status guide cover the details.
Summary: MOTS-c for weight loss in one paragraph
MOTS-c for weight loss rests on mouse work: in diet-induced obese mice, the peptide limited weight gain through AMPK. Human evidence is limited to natural levels and exercise. No trial has shown injected MOTS-c reduces weight in people, so the sensible step is a provider review, not a dosage chart.
Frequently asked questions about MOTS-c for weight loss
Does MOTS-c for weight loss work in humans?
Nobody knows yet. MOTS-c for weight loss has been studied mainly in mice fed a high-fat diet, where it limited weight gain. No published controlled trial has tested injected MOTS-c for weight loss in people, so there is no human evidence that it reduces body weight.
What did the mouse studies on MOTS-c weight loss show?
In the 2015 study that first described the peptide, MOTS-c treatment prevented diet-induced obesity and high-fat-diet insulin resistance in mice. A 2019 follow-up in diet-induced obese mice linked it to higher fat burning (beta-oxidation) and less fat build-up in the liver.
Is MOTS-c for weight loss the same as a GLP-1 medicine?
No. GLP-1 medicines such as semaglutide and tirzepatide work on appetite and blood sugar hormones and were tested in large randomized human trials before FDA approval for weight management. MOTS-c is a mitochondrial peptide studied for AMPK and muscle metabolism, mostly in animals, and it is not FDA-approved.
Can MOTS-c fat loss replace diet and exercise?
There is no evidence for that. MOTS-c is called an exercise mimetic because it switches on some exercise-related energy pathways in mice. That is a research label, not a substitute for nutrition, activity or medical care.
Is MOTS-c obesity research showing lower MOTS-c levels in people with obesity?
The findings are mixed. One small study found similar blood MOTS-c levels in lean and obese adults, while a 2024 meta-analysis reported lower levels in people with diabetes and higher levels in people with obesity. Blood levels alone do not show whether taking MOTS-c helps.
Is the mots-c peptide FDA-approved for weight loss?
No. MOTS-c is not FDA-approved for any use, including weight loss. In July 2026 an FDA advisory committee voted to recommend adding it to the bulk substances list for compounding, but that vote is non-binding and pending FDA rulemaking. Since October 28, 2026, an interim HHS enforcement discretion policy covers single-ingredient MOTS-c injections under strict conditions; it is temporary and is not FDA approval.
Who might discuss MOTS-c for weight loss with a provider?
Adults curious about metabolic health who want a licensed provider to weigh the limited evidence. Pregnancy, breastfeeding and diabetes medication call for particular caution. At telos rx, a US-licensed provider reviews an online intake asynchronously and decides whether a prescription is appropriate.
Now you know what the MOTS-c weight loss research does and does not show. If you want a licensed provider to decide whether it fits you, start a short online intake.
Explore MOTS-c at telos rxThis article is for general education and is not medical advice. MOTS-c is not FDA-approved for any use, and compounded MOTS-c has not been evaluated by the FDA for safety, effectiveness or quality. All prescriptions are subject to medical approval by a licensed provider; approval is not guaranteed. Individual experiences vary. telos rx is an online-first, asynchronous telehealth service, and medications are compounded by a licensed US pharmacy. MOTS-c is prohibited in sport under the WADA Prohibited List.